THE UNITED STATES PATENT AND TRADEMARK OFFICE ation of : Bechtold-Peters, K.) Art Unit: 1615 U.S. Appln. No. : 10/054,592) Examiner: Confirmation No.: 7703 U.S. Filing Date : January 22, 2002 Title of Invention: Medical Formulation Containing a Muscarinic Agonist Attny. Docket No.: 1/1187 Commissioner for Patents Washington, D.C. 20231 November 14, 2002 TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT Sir: Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and 1.97, as more specifically described hereinbelow. X This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 33 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114. 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by: A statement as specified in 37 C.F.R. §1.97(e) [see below]; or The fee set forth in 37 C.F.R. §1.17(p).

02-2955.

\$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No.

The Commissioner is hereby authorized to charge payment of the

§1.97(c)	1.97(d). This Statement is being filed after the period specified in 37 C.F.R. but on or before payment of the issue fee. This Statement is accompanied by a t as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
<u> </u>	97(e).
cc	Each item of information contained in the instant information disclosure atement was first cited in any communication from a foreign patent office in a punterpart foreign application not more than three (3) months prior to the filing of e instant information disclosure statement; or
fo ma in § l	No item of information contained in the instant information disclosure attement was cited in a communication from a foreign patent office in a counterpart reign application, and, to the knowledge of the person signing this certification after aking reasonable inquiry, no item of information contained in the instant formation disclosure statement was known to any individual designated in 37 C.F.R56(c) more than three (3) months prior to the filing of the instant information sclosure statement.
	The fee set forth in 37 C.F.R. §1.17(p).
	The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
disclosure counterpar in section	704(d). Each item of information contained in the accompanying information estatement was cited in a communication from a foreign patent office in a rt application, which communication was not received by any individual designated 1.56(c) more than thirty (30) days prior to the filing of the accompanying on disclosure statement.

The Commissioner is hereby authorized to charge payment of any additional filing quired under 37 C.F.R. §1.16 and any patent application processing fees under 37 §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

ate copies of this form are enclosed.

Respectfully submitted, fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Timothy X. Witkewski Attorney for Applicant(s)

Reg. No. 40,232

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877

Tel.: (203) 798-4310

deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

I hereby certify that this correspondence is being

Commissioner for Patents Washington, DC 20231

on November 14, 2002

By: Timothy X. Witkowski

Reg. No. . 40,232

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449A/PTO

NOV 1 9 2002

TRADEN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complet if Kn wn				
Application Number	10/054,592			
Filing Date	January 22, 2002			
First Named Inventor	Bechtold-Peters, K. et al			
Art Unit	1615			
Examiner Name	To be assigned			
Attorney Docket Number	1/1187			

	U.S. PATENT DOCUMENTS				
Examiner Initials		Document Number Number- Kind Code ² (if known	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	l	US-			
		US-			**************************************
		US-			
		US-		A STATE OF THE STA	` ^
		US-			
		US-			
		US-			Ko A C
		US-		•	CX OL
		US-	**************************************		C 2 1
		US-			1/2
		us-		****	
		US-			7005
		US-			100
		US-			3
		US-			
		US-			**************************************
		US-		**************************************	######################################
		US-	THE CONTRACT OF STATE OF THE PARTY OF THE PA	***************************************	***************************************
		US-			
		US-	W- B - L		

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code 3 -Number 4 - Kind Code 5 (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
		DE 198 51 126 A1	11/05/2000	Boehringer Ingelheim		
				Pharma KG	The state of the s	
		EP 0 370 415	05/30/1990	Boehringer Ingelheim KG		
		WO98/30243	07/16/1998	Warner-Lambert	**************************************	
		WO 98/46601	10/22/1998	Eli Lilly and Co.		
		WO 98/46225	10/22/1998	Eli Lilly and Co.		
		ANTERIOR ANTERIOR STATE OF THE PROPERTY OF THE			times which in the control of the co	
		,			NAMES OF THE PROPERTY OF THE P	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Onlormance and not considered. Include copy of this form with hext communication to applicant.

1 Applicant's unique citation designation number (optional).

2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.